Evotec SE

Evotec SE is a leading life science company specializing in drug discovery and development for pharmaceutical and biotechnology partners. Founded in 1993 in Hamburg, Germany, it operates through two key segments: EVT Execute, which delivers integrated drug discovery solutions on a fee-for-service basis or via milestone and royalty structures, and EVT Innovate, focusing on proprietary projects, assets, and platforms developed internally or with academic collaborators. Evotec integrates breakthrough science, AI-driven innovation, and advanced technologies across small molecules, biologics, and cell therapies, supported by proprietary tools like Molecular Patient Databases, PanOmics, and iPSC-based disease modeling. The company targets underserved therapeutic areas including neurology, oncology, metabolic, infectious, cardiovascular, and immunological diseases. With over 4,800 experts across sites in Europe and the U.S., generating significant revenue from the American market, Evotec partners with all Top 20 pharma companies and more than 800 biotechs, academic institutions, and healthcare stakeholders, playing a pivotal role in accelerating therapies from concept to clinic.